Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 11/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059189 | 0.90 | FLT3 (0.45) | FLT3KDRFGFR3GRM2FYN | |
| SCHEMBL6921936 | 0.88 | FLT3 (0.44) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6922507 | 0.88 | FLT3 (0.43) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6922781 | 0.88 | FLT3 (0.51) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6923078 | 0.85 | FLT3 (0.42) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6920749 | 0.85 | FLT3 (0.42) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6922723 | 0.83 | FLT3 (0.41) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6922510 | 0.83 | KDR (0.48) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6921226 | 0.83 | GRM5 (0.42) | — | |
| SCHEMBL6922096 | 0.82 | FLT3 (0.44) | FLT3KDRFGFR3GRM2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | FLT3 2845/4885KDR 3370/4885FGFR3 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.